- June 5, 2016
-- Novartis" Jordan launches first of its kind drug in the world to manage Systolic Heart Failure
Novartis announced the launching of its new drug; LCZ696 (sacubitril/
valsartan) in the Jordanian market, the first of its kind in the world to manage Systolic Heart failure. This has come during a special scientific meeting, held by Novartis Jordan at Royal hotel on Tuesday, 31 May 2016.
Systolic Heart failure is life-threatening to patients and causes debilitation of the body due to the fact that the heart is unable to pump sufficient amount of blood. Among its symptoms; shortness of breath, extreme fatigue, in addition to fluid retention. These symptoms are slow in progress and exacerbate over time which may negatively impacts the quality of patients' lives.
The importance of this step comes after publication of the PARADIGM-HF data analysis, showcased during the 65th Annual Scientific Conference organized by the American Cardiovascular Faculty in Chicago. The analysis showed that (sacubitril/
valsartan) LCZ696 successfully manages Chronic Systolic Heart Failure patients. The data has also showed about a 20% reduction in cardiovascular death or heart failure hospitalization.
The benefit of this drug is further enhanced by being the first drug that reduces the strain on the failing heart by enhancing the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-
aldosterone system (RAAS), while other heart failure drugs only block the harmful effects of the overactive RAAS. It contains the neprilysin inhibitor sacubitril, which is a new molecular entity, and the angiotensin receptor blocker (ARB) valsartan.
The introduction of this drug into the Jordanian market represents a window of hope for heart failure patients who are taking higher or lower doses of beta blockers and those who are dependable on an implantable cardioverter-